[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cell-based Assays Market by Product & Service (Reagents, Microplate, Cell Lines, Assay Kits, Instrument & Software, Services), Application (Drug Discovery, Research), End User (CROs, Pharmaceutical Companies, Research Institutes) - Global Forecast to 2025

March 2021 | 231 pages | ID: C43738E94D3EN
MarketsandMarkets

US$ 4,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The cell-based assays market is projected to reach USD 22.0 billion by 2025 from USD 14.9 billion in 2020, at a CAGR of 8.1% during the forecast period. The growing preference for cell-based assays in drug discovery, increasing funding for cell-based research, and growth in the number of drug discovery activities are the key factors supporting the growth of the market.

“By product and service, the consumables segment accounted for the largest share of the cell-based assays market”

The cell-based assays market is categorized into major three product and service categories, consuambles, instrumenet & software and services. Consumables dominated the market in 2019. The large share of this segment can be attributed to the extensive use and repeated purchase of consumables by pharmaceutical and biopharmaceutical companies and the rising number of preliminary studies for the development of therapeutics.

“Asia Pacific: The fastest-growing region in the cell-based assays market.”

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the government initiatives to increase funding in biopharmaceuticals, growing R&D spending, and partnerships for life science research.

“North America: the largest share of the cell-based assays market”

North America accounted for the largest share of the cell-based assays market. Factors such as the to the availability of government and private funding for life science research, the growing penetration of CROs, comprehensive drug development regulations, and the rapid adoption of advanced technologies in the region are the major factors driving the market growth.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:
  • By Respondent– Supply Side- 70%, Demand Side- 30%
  • By Designation— Executives- 25%, CXOs, Directors- 20%, Managers - 55%
  • By Region— North America - 50%, Europe - 20%, APAC – 20%, LATAM- 5%, MEA- 5%
The cell-based assays market is dominated by a few globally established players such as Becton, Dickinson and Company (US), Cell Signaling Technology, Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Promega Corporation (US), Charles River Laboratories (US), Lonza (Switzerland), BioAgilytix Labs (US), Reaction Biology Corporation (US), AAT Bioquest (US), IBR Inc. (Switzerland), PBL Assay Science (US), Eurofins (US), InvivoGen (US), TopoGEN, Inc. (US), Ca3 Bioscience (Neuromics) (US), Cell Biolabs, Inc. (US), Carna Biosciences, Inc. (Japan), Dojindo Molecular Technologies, Inc. (US), Enzo Life Sciences, Inc. (US), BPS Bioscience, Inc. (US), SGS SA (Switzerland), and MLM Medical Laboratories (MD Biosciences) (US).

Research Coverage:

The report segments the cell-based assays market based on region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa), Consumables (Reagents, Assay Kits (Reporter Gene Assays, Second Messenger Assays, Cell Growth Assays, Cell Death Assays, Other Assay Kits), Cell Lines (Immortalized Cell Lines, Primary Cell Lines, Stem Cell Lines), Microplates, Probes & Labels, Other Consumables), Instruments & Software, Services, Application (Drug Discovery (Pharmacodynamic Studies, Pharmacokinetic Studies, Toxicity Studies), Basic Research and Other Application), End users (Pharmaceutical & Biopharmaceutical Companies, CROs, and Academic & Research Institutes).

The report also provides a comprehensive review of market drivers, challenges, and opportunities in the cell-based assays market

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the cell-based assays market and provides them information on key market drivers, challenges, and opportunities
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
  1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
  1.3.1 MARKETS COVERED
  1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
  2.1.1 SECONDARY DATA
  2.1.2 PRIMARY DATA
FIGURE 1 PRIMARY SOURCES
FIGURE 2 CELL-BASED ASSAYS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 – REVENUE SHARE ANALYSIS, 2019
FIGURE 4 AVERAGE MARKET SIZE ESTIMATION, 2019
FIGURE 5 CELL-BASED ASSAYS MARKET: CAGR PROJECTIONS, 2020–2025
FIGURE 6 CELL-BASED ASSAYS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RISK ANALYSIS

3 EXECUTIVE SUMMARY

FIGURE 8 CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2020 VS. 2025 (USD MILLION)
FIGURE 9 CELL-BASED ASSAYS MARKET, BY APPLICATION, 2020 VS. 2025 (USD MILLION)
FIGURE 10 CELL-BASED ASSAYS MARKET, BY END USER (USD MILLION)
FIGURE 11 GEOGRAPHICAL SNAPSHOT: CELL-BASED ASSAYS MARKET

4 PREMIUM INSIGHTS

4.1 CELL-BASED ASSAYS MARKET OVERVIEW
FIGURE 12 RISING DRUG DISCOVERY ACTIVITY IS DRIVING THE DEMAND FOR CELL-BASED ASSAYS
4.2 NORTH AMERICA: CELL-BASED ASSAYS MARKET SHARE (2019)
FIGURE 13 CONSUMABLES COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN CELL-BASED ASSAYS MARKET IN 2019
4.3 CELL-BASED ASSAYS MARKET SHARE, BY APPLICATION (2019)
FIGURE 14 DRUG DISCOVERY COMMANDED THE LARGEST SHARE OF THE CELL-BASED ASSAYS MARKET IN 2019
4.4 CELL-BASED ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 15 CHINA IS THE FASTEST-GROWING MARKET FOR CELL-BASED ASSAYS

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 16 CELL-BASED ASSAYS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  5.2.1 DRIVERS
    5.2.1.1 Growing preference for cell-based assays in drug discovery
    5.2.1.2 Increasing funding for cell-based research
    5.2.1.3 Growth in the number of drug discovery activities
  5.2.2 RESTRAINTS
    5.2.2.1 High cost of instruments and restrictions on reagent use
    5.2.2.2 Lack of infrastructure for cell-based research in emerging economies
  5.2.3 OPPORTUNITIES
    5.2.3.1 Emerging economies
    5.2.3.2 Growing risk of pandemics and communicable diseases
    5.2.3.3 Application of novel cell-based assays in cancer research
5.3 IMPACT OF COVID-19 ON THE CELL-BASED ASSAYS MARKET
5.4 VALUE CHAIN ANALYSIS
FIGURE 17 CELL-BASED ASSAYS MARKET: VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 18 CELL-BASED ASSAYS MARKET: SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
FIGURE 19 CELL-BASED ASSAYS MARKET: ECOSYSTEM ANALYSIS

6 CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE

6.1 INTRODUCTION
TABLE 1 CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
6.2 CONSUMABLES
TABLE 2 CONSUMABLES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 3 NORTH AMERICA: CONSUMABLES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 4 EUROPE: CONSUMABLES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 5 ASIA PACIFIC: CONSUMABLES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 6 CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
  6.2.1 REAGENTS
    6.2.1.1 Expanded applications of reagents propel market growth for the segment
TABLE 7 REAGENTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 8 NORTH AMERICA: REAGENTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 9 EUROPE: REAGENTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 10 ASIA PACIFIC: REAGENTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.2.2 ASSAY KITS
TABLE 11 ASSAY KITS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 12 NORTH AMERICA: ASSAY KITS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 13 EUROPE: ASSAY KITS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 14 ASIA PACIFIC: ASSAY KITS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 15 ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
    6.2.2.1 Reporter gene assays
      6.2.2.1.1 Reporter gene assays can be used with limited resources to establish HTS platforms, representing opportunities for small laboratories with limited resources
TABLE 16 REPORTER GENE ASSAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 17 NORTH AMERICA: REPORTER GENE ASSAYS REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 18 EUROPE: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 19 ASIA PACIFIC: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    6.2.2.2 Cell growth assays
      6.2.2.2.1 Cell viability and cell proliferation assays are the two most important in vitro quantification techniques for assessing cell growth
TABLE 20 CELL GROWTH ASSAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 21 NORTH AMERICA: CELL GROWTH ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 22 EUROPE: CELL GROWTH ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 23 ASIA PACIFIC: CELL GROWTH ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    6.2.2.3 Second messenger assays
      6.2.2.3.1 These assays are used to detect and characterize all compound classes
TABLE 24 SECOND MESSENGER ASSAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 25 NORTH AMERICA: SECOND MESSENGER ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 26 EUROPE: SECOND MESSENGER ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 27 ASIA PACIFIC: SECOND MESSENGER ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    6.2.2.4 Cell death assays
      6.2.2.4.1 Cell death quantification is essential to identify how potential drugs could inhibit or enhance molecular targets
TABLE 28 CELL DEATH ASSAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 29 NORTH AMERICA: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 30 EUROPE: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 31 ASIA PACIFIC: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    6.2.2.5 Other assay kits
TABLE 32 OTHER ASSAY KITS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 33 NORTH AMERICA: OTHER ASSAY KITS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 34 EUROPE: OTHER ASSAY KITS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 35 ASIA PACIFIC: OTHER ASSAY KITS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.2.3 MICROPLATES
    6.2.3.1 Extensive use of microplates for assay development is encouraging the consumption of these products
TABLE 36 MICROPLATES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 37 NORTH AMERICA: MICROPLATES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 38 EUROPE: MICROPLATES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 39 ASIA PACIFIC: MICROPLATES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.2.4 CELL LINES
TABLE 40 CELL LINES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 41 NORTH AMERICA: CELL LINES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 42 EUROPE: CELL LINES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 43 ASIA PACIFIC: CELL LINES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 44 CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
    6.2.4.1 Immortalized cell lines
      6.2.4.1.1 Immortalized cell lines are widely used owing to their ease of use, cost-effectiveness, and high availability of material
TABLE 45 IMMORTALIZED CELL LINES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 46 NORTH AMERICA: IMMORTALIZED CELL LINES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 47 EUROPE: IMMORTALIZED CELL LINES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 48 ASIA PACIFIC: IMMORTALIZED CELL LINES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    6.2.4.2 Primary cell lines
      6.2.4.2.1 Primary cell lines find demand in a range of applications
TABLE 49 PRIMARY CELL LINES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 50 NORTH AMERICA: PRIMARY CELL LINES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 51 EUROPE: PRIMARY CELL LINES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 52 ASIA PACIFIC: PRIMARY CELL LINES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    6.2.4.3 Stem cell lines
      6.2.4.3.1 Stem cell lines find applications in therapy development and regenerative medicine
TABLE 53 STEM CELL LINES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 54 NORTH AMERICA: STEM CELL LINES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 55 EUROPE: STEM CELL LINES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 56 ASIA PACIFIC: STEM CELL LINES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.2.5 PROBES & LABELS
    6.2.5.1 Effective labeling of cells helps in studying cellular events
TABLE 57 PROBES & LABELS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 58 NORTH AMERICA: PROBES & LABELS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 59 EUROPE: PROBES & LABELS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 60 ASIA PACIFIC: PROBES & LABELS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  6.2.6 OTHER CONSUMABLES
TABLE 61 OTHER CONSUMABLES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 62 NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 63 EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 64 ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
6.3 INSTRUMENTS & SOFTWARE
  6.3.1 TECHNOLOGICAL ADVANCEMENTS AND AUTOMATION IN INSTRUMENTS AND RISING USE OF SOFTWARE DRIVE THE GROWTH OF THE SEGMENT
TABLE 65 INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 66 NORTH AMERICA: INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 67 EUROPE: INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 68 ASIA PACIFIC: INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
6.4 SERVICES
  6.4.1 RISING NUMBER OF CROS PROVIDING DRUG DISCOVERY AND SCREENING SERVICES TO ACCELERATE SEGMENT GROWTH
TABLE 69 SERVICES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 70 NORTH AMERICA: SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 71 EUROPE: SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 72 ASIA PACIFIC: SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)

7 CELL-BASED ASSAYS MARKET, BY APPLICATION

7.1 INTRODUCTION
TABLE 73 GLOBAL CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
7.2 DRUG DISCOVERY
TABLE 74 CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 75 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 76 EUROPE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 77 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 78 CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
  7.2.1 TOXICITY STUDIES
    7.2.1.1 Increasing adoption of high-content screening for cytotoxicity testing to fuel growth in this segment
TABLE 79 TOXICITY STUDIES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 80 NORTH AMERICA: TOXICITY STUDIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 81 EUROPE: TOXICITY STUDIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 82 ASIA PACIFIC: TOXICITY STUDIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  7.2.2 PHARMACOKINETIC STUDIES
    7.2.2.1 Rising importance of ADME studies in pharmacokinetics to propel the demand for advanced cell-based assay technologies
TABLE 83 PHARMACOKINETIC STUDIES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 84 NORTH AMERICA: PHARMACOKINETIC STUDIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 85 EUROPE: PHARMACOKINETIC STUDIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 86 ASIA PACIFIC: PHARMACOKINETIC STUDIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
  7.2.3 PHARMACODYNAMIC STUDIES
    7.2.3.1 Expanded use of cell-based assays to study pharmacodynamics to propel the growth of the segment
TABLE 87 PHARMACODYNAMIC STUDIES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 88 NORTH AMERICA: PHARMACODYNAMIC STUDIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 89 EUROPE: PHARMACODYNAMIC STUDIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 90 ASIA PACIFIC: PHARMACODYNAMIC STUDIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
7.3 BASIC RESEARCH
  7.3.1 INCREASING FUNDING BY GOVERNMENT INSTITUTES FOR BASIC RESEARCH TO DRIVE THE DEMAND FOR CELL-BASED ASSAY PRODUCTS & SERVICES
TABLE 91 CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 92 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 93 EUROPE: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 94 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
7.4 OTHER APPLICATIONS
TABLE 95 CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 96 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 97 EUROPE: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 98 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)

8 CELL-BASED ASSAYS MARKET, BY END USER

8.1 INTRODUCTION
TABLE 99 CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  8.2.1 GROWING R&D ACTIVITIES TO DRIVE THE DEMAND FOR CELL-BASED ASSAYS IN THIS END-USER SEGMENT
TABLE 100 CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 101 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 102 EUROPE: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 103 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION)
8.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
  8.3.1 GROWTH IN OUTSOURCING TO DRIVE THE DEMAND FOR CELL-BASED ASSAYS IN CONTRACT RESEARCH ORGANIZATIONS
TABLE 104 RECENT MERGERS & ACQUISITIONS AMONG CONTRACT RESEARCH ORGANIZATIONS
TABLE 105 CELL-BASED ASSAYS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 106 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 107 EUROPE: CELL-BASED ASSAYS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 108 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
8.4 ACADEMIC & RESEARCH INSTITUTES
  8.4.1 GROWING FOCUS OF ACADEMIC INSTITUTIONS ON DEVELOPING ASSAYS FOR INNOVATIVE APPLICATIONS TO DRIVE THE DEMAND FOR CELL-BASED ASSAYS IN THIS END-USER SEGMENT
TABLE 109 CELL-BASED ASSAYS MARKET FOR ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2018–2025 (USD MILLION)
TABLE 110 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 111 EUROPE: CELL-BASED ASSAYS MARKET FOR ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 112 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION)

9 CELL-BASED ASSAYS MARKET, BY REGION

9.1 INTRODUCTION
TABLE 113 CELL-BASED ASSAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 20 NORTH AMERICA: CELL-BASED ASSAYS MARKET SNAPSHOT
TABLE 114 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 115 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 116 NORTH AMERICA: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 117 NORTH AMERICA: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 118 NORTH AMERICA: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 119 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 120 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 121 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
  9.2.1 US
    9.2.1.1 With growing R&D funding and recent drug approvals, the US dominates the North American cell-based assays market
TABLE 122 US: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 123 US: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 124 US: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 125 US: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 126 US: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 127 US: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 128 US: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
  9.2.2 CANADA
    9.2.2.1 Strategic partnerships and collaborations are supporting the growth of the market in Canada
TABLE 129 CANADA: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 130 CANADA: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 131 CANADA: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 132 CANADA: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 133 CANADA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 134 CANADA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 135 CANADA: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
9.3 EUROPE
TABLE 136 EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 137 EUROPE: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 138 EUROPE: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 139 EUROPE: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 140 EUROPE: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 141 EUROPE: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 142 EUROPE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 143 EUROPE: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
  9.3.1 GERMANY
    9.3.1.1 Germany dominates the cell-based assays market in Europe
TABLE 144 GERMANY: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 145 GERMANY: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 146 GERMANY: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 147 GERMANY: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 148 GERMANY: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 149 GERMANY: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 150 GERMANY: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
  9.3.2 UK
    9.3.2.1 Focus on cancer research funding will increase the demand for cell-based assays in the country
TABLE 151 UK: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 152 UK: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 153 UK: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 154 UK: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 155 UK: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 156 UK: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 157 UK: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
  9.3.3 FRANCE
    9.3.3.1 Increase in R&D funding to drive the growth of the market
TABLE 158 FRANCE: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 159 FRANCE: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 160 FRANCE: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 161 FRANCE: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 162 FRANCE: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 163 FRANCE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 164 FRANCE: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
  9.3.4 ITALY
    9.3.4.1 Strategic collaborations in drug discovery have promoted the growth of the cell-based assays market in Italy
TABLE 165 ITALY: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 166 ITALY: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 167 ITALY: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 168 ITALY: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 169 ITALY: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 170 ITALY: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 171 ITALY: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
  9.3.5 SPAIN
    9.3.5.1 Availability of funding from private and public organizations is aiding the market growth
TABLE 172 SPAIN: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 173 SPAIN: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 174 SPAIN: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 175 SPAIN: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 176 SPAIN: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 177 SPAIN: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 178 SPAIN: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
  9.3.6 REST OF EUROPE
TABLE 179 ROE: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 180 ROE: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 181 ROE: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 182 ROE: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 183 ROE: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 184 ROE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 185 ROE: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 21 ASIA PACIFIC: CELL-BASED ASSAYS MARKET SNAPSHOT
TABLE 186 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 187 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 188 ASIA PACIFIC: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 189 ASIA PACIFIC: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 190 ASIA PACIFIC: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 191 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 192 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 193 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
  9.4.1 CHINA
    9.4.1.1 Rising R&D capabilities and accelerated drug discovery have created a demand for cell-based assays products and services
TABLE 194 CHINA: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 195 CHINA: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 196 CHINA: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 197 CHINA: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 198 CHINA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 199 CHINA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 200 CHINA: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
  9.4.2 JAPAN
    9.4.2.1 Government programs to encourage drug discovery has increased the demand for cell-based assays in Japan
TABLE 201 JAPAN: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 202 JAPAN: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 203 JAPAN: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 204 JAPAN: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 205 JAPAN: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 206 JAPAN: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 207 JAPAN: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
  9.4.3 INDIA
    9.4.3.1 Market growth in India is attributed to increasing investments in R&D and funding for life sciences research
TABLE 208 INDIA: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 209 INDIA: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 210 INDIA: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 211 INDIA: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 212 INDIA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 213 INDIA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 214 INDIA: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
  9.4.4 REST OF ASIA PACIFIC
TABLE 215 ROAPAC: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 216 ROAPAC: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 217 ROAPAC: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 218 ROAPAC: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 219 ROAPAC: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 220 ROAPAC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 221 ROAPAC: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
9.5 LATIN AMERICA
  9.5.1 RISING NUMBER OF CLINICAL TRIAL SITES AND GROWING PARTICIPATION OF ACADEMIC INSTITUTES IN RESEARCH TO ACCELERATE MARKET GROWTH
TABLE 222 LATAM: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 223 LATAM: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 224 LATAM: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 225 LATAM: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 226 LATAM: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 227 LATAM: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 228 LATAM: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
  9.6.1 GOVERNMENT EFFORTS TO INCREASE RESEARCH WILL FUEL THE DEMAND FOR CELL-BASED ASSAYS IN THE REGION
TABLE 229 MEA: CELL-BASED ASSAYS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 230 MEA: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 231 MEA: ASSAY KITS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 232 MEA: CELL LINES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 233 MEA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 234 MEA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
TABLE 235 MEA: CELL-BASED ASSAYS MARKET, BY END USER, 2018–2025 (USD MILLION)

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW
FIGURE 22 MARKET EVALUATION FRAMEWORK
10.2 REVENUE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 23 MARKET SHARE ANALYSIS: 2019
TABLE 236 CELL-BASED ASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
10.3 CELL-BASED ASSAYS MARKET: COMPANY EVALUATION QUADRANT, 2019
  10.3.1 STARS
  10.3.2 EMERGING LEADERS
  10.3.3 PERVASIVE COMPANIES
  10.3.4 EMERGING COMPANIES
FIGURE 24 CELL-BASED ASSAYS MARKET: COMPANY EVALUATION MATRIX, 2019
10.4 CELL-BASED ASSAYS MARKET: START-UP/SME EVALUATION MATRIX, 2019
  10.4.1 PROGRESSIVE COMPANIES
  10.4.2 STARTING BLOCKS
  10.4.3 RESPONSIVE COMPANIES
  10.4.4 DYNAMIC COMPANIES
FIGURE 25 CELL-BASED ASSAYS MARKET: STARTUP/SME EVALUATION MATRIX, 2019
10.5 KEY MARKET DEVELOPMENTS
  10.5.1 KEY PRODUCT LAUNCHES
  10.5.2 KEY ACQUISITIONS
  10.5.3 KEY PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
  10.5.4 KEY EXPANSIONS

11 COMPANY PROFILES

(Business overview, Products offered, Recent developments, SWOT analysis, MNM view)*
11.1 THERMO FISHER SCIENTIFIC
FIGURE 26 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
11.2 DANAHER CORPORATION
FIGURE 27 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
11.3 MERCK KGAA
FIGURE 28 MERCK KGAA: COMPANY SNAPSHOT (2019)
11.4 BECTON, DICKINSON AND COMPANY
FIGURE 29 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
11.5 LONZA GROUP
FIGURE 30 LONZA GROUP AG: COMPANY SNAPSHOT
11.6 PERKINELMER
FIGURE 31 PERKINELMER: COMPANY SNAPSHOT (2019)
11.7 CHARLES RIVER LABORATORIES
FIGURE 32 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2019)
11.8 EUROFINS SCIENTIFIC SE
FIGURE 33 EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT (2019)
11.9 ENZO BIOCHEM
FIGURE 34 ENZO BIOCHEM: COMPANY SNAPSHOT (2019)
11.10 PROMEGA CORPORATION
11.11 CARNA BIOSCIENCES, INC.
FIGURE 35 CARNA BIOSCIENCES: COMPANY SNAPSHOT (2020)
11.12 CELL BIOLABS
11.13 CELL SIGNALING TECHNOLOGY
11.14 BIOAGILYTIX LABS INC.
11.15 REACTION BIOLOGY CORPORATION
11.16 AAT BIOQUEST, INC.
11.17 PBL ASSAY SCIENCE
11.18 INVIVOGEN
11.19 CA3 BIOSCIENCES INC. (NEUROMICS)
11.20 BPS BIOSCIENCE
*Business overview, Products offered, Recent developments, SWOT analysis, MNM view might not be captured in case of unlisted companies.

12 APPENDIX

12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS

The bottom-up approach was implemented for arriving at the overall market size of the cell-based  assays  market,  based  on  the  market  size  of  major  product  submarkets  such  as consumables,  instruments,  software,  and  services.  Similarly  the  overall  consumables  and instruments  market  was  derived  by  summing  up  the  market  sizes  of  different  types  of consumables  and  instruments.  Further,  the  total  software  and  services  market  (which  was validated using the top-down approach) was added to the total consumables and instruments market to derive the overall market size of cell-based assays market.

This overall market size was used in the top-down procedure to estimate the market sizes of all other individual market segments and subsegments by product, application, end user, and geography using percentage splits from secondary and primary research. The market sizes of different products submarkets obtained by the bottom-up approach were validated by the top-down approach. Thus, using a combination of top-down and bottom-up approaches, the overall cell-based assay market size was arrived at.

Cell-based assays have an edge over in vitro biochemical assays in several aspects. Cell-based assays are believed to provide more precise, tissue-specific responses in a biologically relevant microenvironment, in comparison with biochemical assays. The drug responses in biochemical assays may not resemble the drug responses in a cellular context. Moreover, it is not possible to  prepare  or  purify  every  target  for  biochemical  measurement,  thereby  restricting  the applications  of  biochemical  assays.  Owing  to  this,  pharmaceutical  and  biotechnology companies  are  eventually  replacing  biochemical  assays  with  cell-based  assays  in  lead identification and optimization processes of drug discovery. 

Although cell-based assays cannot fully replace animal testing, early phase toxicity screening has been definitely considered to be in the realm of cell-based assays. Conventional methods of  toxicity  and  drug  safety  assessment  involved  animal  testing  which  is  expensive,  time-consuming,  and  low-throughput.  Additionally,  animal  model  studies  are  faced  with  ethical issues, lack of interaction mechanism, and often fail to extrapolate to human drug responses.

Cell-based  assays  enable  relatively  inexpensive  cytotoxicity  studies  which  provide  an  early evidence of toxicity attributes of a potential drug candidate. Recent efforts are directed toward reducing the number of animal tests using high throughput cell-based assays which not only increase drug screening efficiency but also fasten the drug discovery process.

Thus, cell-based assays present a preferable alternative for biochemical assays and animals as a result of their physiological relevance, inherent virtues, and ability to provide efficient, cost-effective, and accelerated drug discovery solutions.



More Publications